FrancophonIA/ELRC3.0 huggingface dataset:
English: The procedure was therefore referred to the CMD(h) and subsequently, to the CHMP under Article 29(4), in April 2010.
Estonian: Seetõttu esitati menetlus inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluse koordineerimisrühmale ning seejärel 2010. aasta aprillis artikli 29 lõike 4 kohaselt inimravimite komiteele.
English: Treatment with bisphosphonates generally also includes treatment with calcium, to support the remineralisation of the skeleton and with colecalciferol (vitamin D3) which increases calcium absorption.
Estonian: Bisfosfonaatraviga kaasneb üldjuhul ka ravi luustiku remineraliseerumist toetava kaltsiumiga ja kolekaltsiferooliga (vitamiin D3), mis parandab kaltsiumi imendumist.
English: Fortipan Combi D 35 mg + 1000 mg/880 IU
Estonian: Actocalcio D3 35 mg + 1000 mg/880 IU
English: The CHMP was of the opinion that the combination pack will simplify the correct dosage regimen compared to the individual products, thereby reducing the risk of interactions.
Estonian: Inimravimite komitee oli seiskohal, et võrreldes üksikpakenditega lihtsustab kombineeritud pakend õigest annustamisrežiimist kinnipidamist, vähendades seeläbi koosmõjude ohtu.
English: The CHMP considered the combination pack of risedronate and calcium plus colecalciferol to be an “exceptional case”, based on the problematic dosing and the risk for interaction prohibiting concomitant intake as per the Guideline for combination products (CHMP/EWP/240/95).
Estonian: Inimravimite komitee luges risedronaadi ning kaltsiumi ja kolekaltsiferooli pakendit „eriliseks juhtumiks”, tuginedes annustamise problemaatilisusele ja koostoimete ohust tingitud samaaegse manustamise keelule kombineeritud preparaatide eeskirja (CHMP/EWP/240/95) kohaselt.
English: (Invented) Name Strength
Estonian: (Ravimi väljamõeldud) nimetus
English: On these grounds, the CHMP did not consider the demonstration of improved compliance to be an absolute requirement for the approval of this combination product.
Estonian: Nendel alustel ei pidanud inimravimite komitee kombineeritud preparaadile heakskiidu andmisel ravijärgimuse paranemise näitamist absoluutseks nõudeks.
English: Scientific conclusions and grounds for positive opinion
Estonian: EUROOPA RAVIMIAMETI ESITATUD TEADUSLIKUD JÄRELDUSED JA POSITIIVSE ARVAMUSE ALUSED
English: The procedure started in November 2009 and the indications applied for are the “treatment of postmenopausal osteoporosis, to reduce the risk of vertebral fractures” and the “treatment of established postmenopausal osteoporosis, to reduce the risk of hip fractures”.
Estonian: Taotluses esitatud näidustused olid „menopausijärgse osteoporoosi ravi selgroolülide murdude ohu vähendamiseks” ja „väljakujunenud menopausijärgse osteoporoosi ravi puusaluu murru ohu vähendamiseks”.
English: Treatment with anti-resorptive agents such as bisphosphonates together with oestrogen replacement therapy can prevent or reduce the loss of bone associated with postmenopausal osteoporosis.
Estonian: (bisfosfonaatidega) koos östrogeeni asendusraviga võib hoida ära või vähendada luukoe kadu, mida seostatakse menopausijärgse osteoporoosiga.
English: List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, applicant and marketing authorisation holders in the Member States
Estonian: RAVIMI(TE) NIMETUSTE, RAVIMVORMI(DE), TUGEVUS(T)E, MANUSTAMISVIISI(DE), TAOTLEJA(TE), MÜÜGILOA HOIDJA(TE) LOETELU LIIKMESRIIKIDES
English: Therefore, the proposed dosage is one risedronate tablet on day 1 followed by one sachet of calcium/colecalciferol daily for day 2 through to day 7, repeating this 7-day sequence each week.
Estonian: Seepärast soovitatakse annustada üks risedronaaditablett 1. päeval ja seejärel 2. kuni 7. päevani üks kotike kaltsiumi/kolekaltsiferooliga kord päevas.
English: Module 5 contained pivotal clinical studies and study reports for the 35 mg risedronate tablet and the calcium plus colecalciferol product as well as the pivotal study for approval of the weekly 35 mg risedronate tablet, in which patients were co-administered calcium and vitamin D, along with 46 relevant clinical literature references.
Estonian: 5. moodul sisaldas peale 46 viite kliinilisele teaduskirjandusele ka kliinilisi alusuuringuid ning uuringuaruandeid risedronaadi 35 mg tablettide ning kaltsiumi- ja kaltsiferoolipreparaatide kohta, samuti alusuuringut, milles lisaks kord nädalas manustatavale 35 mg risedronaaditabletile said patsiendid kaltsiumi ja D-vitamiini.
English: Risedronate sodium is a bisphosphonate that inhibits bone resorption and has been shown to increase bone mass and biomechanical skeletal strength.
Estonian: On näidatud, et see suurendab luukoe massi ja skeleti biomehaanilist tugevust.
English: The Applicant submitted an application for mutual recognition of the marketing authorisation granted by Sweden in 2006 for Fortipan Combi D, a combination product consisting of risedronate sodium 35 mg film-coated tablets together with 1000 mg calcium carbonate and 880 IU colecalciferol effervescent granules.
Estonian: See on risedronaatnaatriumi 35 mg õhukese polümeerikilega kaetud tablettidest ning 1000 mg kaltsiumkarbonaadi ja 880 RÜ kolekaltsiferooli kihisevatest graanulitest koosnev kombineeritud preparaat.
English: Module 3 contained relevant documentation for the risedronate film-coated tablet as well as for the effervescent calcium-colecalciferol effervescent granules, for the drug substance as well as for the drug product.
Estonian: 3. moodul sisaldas risedronaadi õhukese polümeerikattega kaetud tablettide ning kaltsiumikolekaltsiferooli kihisevate graanulite toimeainete ja ravimpreparaatide kohta käivat asjassepuutuvat dokumentatsiooni.
English: Oral use
Estonian: Suukaudne
English: Actocalcio D3
Estonian: Fortipan Combi D
English: This summary was last updated in 12-2015.
Estonian: Kokkuvõtte viimane uuendus: 12-2015.
English: The full EPAR for Zutectra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zutectra kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Zutectra on 30 November 2009.
Estonian: Euroopa Komisjon andis Zutectra müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 30. novembril
English: A risk management plan has been developed to ensure that Zutectra is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Zutectra võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Zutectra?
Estonian: Mis meetmed võetakse, et tagada Zutectra ohutu ja efektiivne kasutamine?
English: Antibodies are proteins naturally found in the blood that help the body to fight infections and other diseases.
Estonian: Antikehad on veres looduslikult esinevad valgud, mis aitavad organismil infektsioonide ja muude haigustega võidelda.
English: The recommended dose normally ranges from 500 IU to 1,000 IU, and exceptionally up to 1,500 IU.
Estonian: Soovitatav annus on tavaliselt 500-1000 RÜ, erandjuhtudel kuni 1500 RÜ.
English: Other information about Zutectra
Estonian: Muu teave Zutectra kohta
English: Zutectra has been studied in one main study involving 30 adults who had undergone liver transplants.
Estonian: Zutectrat uuriti ühes põhiuuringus, milles osales 30 täiskasvanut, kellele oli tehtud maksasiirdamine.
English: Zutectra is given as an injection under the skin once a week or every 2 weeks.
Estonian: Zutectrat manustatakse nahaaluse süstina kord nädalas või iga kahe nädala järel.
English: The patient or caregiver will also be trained on how to keep a treatment diary and what to do if severe side effects occur.
Estonian: Patsiendile või tema hooldajale õpetatakse samuti seda, kuidas pidada ravipäevikut ja mida teha raskete kõrvalnähtude ilmnemisel.
English: Before starting Zutectra, the patient will need to receive medicines that contain the same active substance as in Zutectra, but given into a vein.
Estonian: Enne Zutectra kasutamist peab patsient saama ravimeid, mis sisaldavad sama toimeainet mis Zutectra, kuid mida manustatakse veeni.
English: In another study in 49 patients, Zutectra was given at least one week (approximately 8-11 days) after the liver transplant.
Estonian: Teises uuringus manustati Zutectrat 49 patsiendile vähemalt üks nädal (8-11 päeva) pärast maksasiirdamist.
English: This is a summary of the European public assessment report (EPAR) for Zutectra.
Estonian: See on ravimi Zutectra Euroopa avaliku hindamisaruande kokkuvõte.
English: The CHMP decided that Zutectra's benefits are greater than its risks and recommended that Zutectra be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Zutectra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Zutectra must not be given into a blood vessel.
Estonian: Zutectrat ei tohi manustada veresoonde.
English: For more information about treatment with Zutectra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zutectraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zutectra, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Zutectra omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The most common side effects with Zutectra (seen in between 1 and 10 patients in 100) are reactions at the injection site, such as pain, urticaria (itchy rash), haematoma (blood under the skin) and erythema (reddening of the skin).
Estonian: Zutectra kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on süstekoha reaktsioonid, nagu valu, urtikaaria (nõgeslööve), hematoom (verevalum) ja erüteem (nahapunetus).
English: In the first study, all 23 of the patients who completed treatment had antibody levels above 100 IU per litre.
Estonian: Esimeses uuringus oli kõigil 23 patsiendil, kelle ravikuur oli lõppenud, antikehade sisaldus üle 100 RÜ liitri kohta.
English: Zutectra treatment was started at least three months after the liver transplant.
Estonian: Zutectra kasutamist alustati vähemalt kolm kuud pärast maksasiirdamist.
English: Zutectra injections can be given by the patients themselves or their caregiver once they have been trained appropriately.
Estonian: Zutectrat võib pärast vastava väljaõppe saamist süstida patsient ise või tema hooldaja.
English: In the second study, all of the 49 patients had antibody levels above 100 IU per litre and none of them was re-infected during the 24 weeks of treatment.
Estonian: Teises uuringus oli kõigi 49 patsiendi antikehade sisaldus üle 100 RÜ liitri kohta ja mitte ükski patsient ei taasnakatunud 24 ravinädala jooksul.
English: For the full list of all side effects reported with Zutectra, see the package leaflet.
Estonian: Zutectra kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What is Zutectra?
Estonian: Mis on Zutectra?
English: Zutectra prevents the patient from being re-infected with hepatitis B by keeping the blood levels of human hepatitis B immunoglobulins high enough, so that they can attach to the virus and stimulate the immune system to destroy it.
Estonian: Zutectra hoiab ära patsiendi taasnakatumise B-hepatiiti, säilitades B-hepatiidi inimimmunoglobuliini piisava sisalduse veres, et võimaldada sellel viirusega seonduda ning stimuleerida immuunsüsteemi viirust hävitama.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zutectra.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The main measure of effectiveness was the number of patients who had a blood level of hepatitis B immunoglobulin above 100 IU per litre after 18 to 24 weeks.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kellel oli B-hepatiidi inimimmunoglobuliini sisaldus veres 18-24 nädala järel üle 100 RÜ liitri kohta.
English: Zutectra is used to prevent re-infection with the hepatitis B virus in patients without active infection (i.e. those who test negative for the presence of the hepatitis B protein (HBsAg) and for hepatitis B DNA (HBV-DNA)).
Estonian: Zutectrat kasutatakse B-hepatiidi viirusega taasnakatumise ennetamiseks patsientidel, kelle infektsioon ei ole aktiivne (B-hepatiidi proteiini HBsAg ja B-hepatiidi DNA (HBV-DNA) näitajad on negatiivsed).
English: What is the risk associated with Zutectra?
Estonian: Mis riskid Zutectraga kaasnevad?
English: Why has Zutectra been approved?
Estonian: Miks Zutectra heaks kiideti?
English: The main measure of effectiveness was the number of patients in whom treatment failed, defined as blood levels of hepatitis B immunoglobulins falling below 100 IU per litre or reinfection by hepatitis B virus during the 24 weeks of treatment.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kelle ravi ebaõnnestus, mis oli määratletud B-hepatiidi inimimmunoglobuliini sisalduse vähenemisena veres alla 100 RÜ liitri kohta või B-hepatiidi viirusega taasnakatumisena 24 ravinädala jooksul.
English: Zutectra is used in adults who have had a liver transplant because of liver failure that was caused by hepatitis B infection.
Estonian: Zutectrat kasutatakse täiskasvanutel, kellele on tehtud B-hepatiidi infektsioonist põhjustatud maksapuudulikkuse tõttu maksasiirdamine.
English: The active substance in Zutectra, human hepatitis B immunoglobulin, is a purified antibody extracted from human blood.
Estonian: Zutectra toimeaine B-hepatiidi inimimmunoglobuliin on inimese verest eraldatud puhastatud antikeha.
English: Zutectra treatment starts at least one week after the liver transplant.
Estonian: Zutectra kasutamist alustatakse vähemalt üks nädal pärast maksasiirdamist.
English: It is available as a prefilled syringe containing 500 international units (IU) of the active substance, human hepatitis B immunoglobulin.
Estonian: Seda turustatakse eeltäidetud süstlas, mis sisaldab 500 rahvusvahelist ühikut (RÜ) toimeainet B-hepatiidi inimimmunoglobuliini.
English: Zutectra must not be used in people who are hypersensitive (allergic) to the active substance, to any of the other ingredients or to human immunoglobulins.
Estonian: Zutectrat ei tohi kasutada patsiendid, kes on toimeaine, ravimi mis tahes muu koostisaine või inimimmunoglobuliinide suhtes ülitundlikud (allergilised).
English: Zutectra human hepatitis-B immunoglobulin
Estonian: B-hepatiidi inimimmunoglobuliin
English: Zutectra is a solution for injection.
Estonian: Zutectra on retseptiravim.
English: Zutectra has been shown to be effective at maintaining antibody levels required to protect against hepatitis B re-infection.
Estonian: On tõendatud, et Zutectra säilitas tõhusalt B-hepatiiti taasnakatumise ennetamiseks vajaliku antikehade sisalduse.
English: How does Zutectra work?
Estonian: Kuidas Zutectra toimib?
English: The dose is established based on the patient's blood levels of antibodies against the hepatitis B virus.
Estonian: Annus määratakse vastavalt B-hepatiidi viiruse vastaste antikehade sisaldusele patsiendi veres.
English: What benefit has Zutectra shown during the studies?
Estonian: Milles seisneb uuringute põhjal Zutectra kasulikkus?
English: What is Zutectra used for?
Estonian: Milleks Zutectrat kasutatakse?
English: This level is considered adequate to protect against re-infection with the hepatitis B virus.
Estonian: Seda peetakse B-hepatiidi viirusega taasnakatumise ennetamiseks piisavaks.
English: The use of standard antiviral medicines to prevent hepatitis B re-infection should be considered together with Zutectra.
Estonian: Tuleb kaaluda Zutectra kasutamist koos B-hepatiiti taasnakatumise ennetamiseks ettenähtud tavaliste viiruseravimitega.
English: How is Zutectra used?
Estonian: Kuidas Zutectrat kasutatakse?
English: How has Zutectra been studied?
Estonian: Kuidas Zutectrat uuriti?
English: 90 (3 x 30) tablets (multipack)
Estonian: 90 (3 x 30) tabletti (mitmikpakend)
English: Oral Suspension Oral use bottle (glass)
Estonian: Oral Suspension Suukaudne pudel (klaas) 200 ml
English: Other information about Taltz
Estonian: Muu teave Taltzi kohta
English: What measures are being taken to ensure the safe and effective use of Taltz?
Estonian: Mis meetmed võetakse, et tagada Taltzi ohutu ja efektiivne kasutamine?
English: Taltz must not be given to patients who have potentially serious infections such as tuberculosis.
Estonian: Taltzi ei tohi kasutada patsiendid, kellel on potentsiaalselt rasked infektsioonid, näiteks tuberkuloos.
English: The full EPAR and risk management plan summary for Taltz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Taltzi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Taltz is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Taltzi võimalikult ohutu kasutamine.
English: The first dose of 160 mg (two injections) is followed by an injection of 80 mg every two weeks for the first 12 weeks and every 4 weeks thereafter.
Estonian: Esimesele 160 mg annusele (kaks süstet) järgneb üks 80 mg süste iga 2 nädala järel esimese 12 nädala jooksul ja seejärel iga 4 nädala järel.
English: It is used in adults who require systemic treatment (treatment with medicines affecting the whole body).
Estonian: Taltzi kasutatakse täiskasvanutel, kes vajavad süsteemset ravi (ravi kogu organismile toimivate ravimitega).
English: Taltz ixekizumab
Estonian: Taltz iksekisumaab
English: What is Taltz and what is it used for?
Estonian: Mis on Taltz ja milleks seda kasutatakse?
English: Why is Taltz approved?
Estonian: Miks Taltz heaks kiideti?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Taltz's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Taltzi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: This is a summary of the European public assessment report (EPAR) for Taltz.
Estonian: See on ravimi Taltz Euroopa avaliku hindamisaruande kokkuvõte.
English: What are the risks associated with Taltz?
Estonian: Mis riskid Taltziga kaasnevad?
English: After further treatment with Taltz every 4 weeks for 48 weeks, 78% of patients had clear or nearly clear skin.
Estonian: Pärast edasist ravi Taltziga iga 4 nädala järel 48 nädala jooksul oli patsiente, kelle nahk oli puhas või peaaegu puhas, 78%.
English: The most common side effects with Taltz (which may affect more than 1 in 10 people) are pain and redness at the injection site, and nose, throat or chest infections.
Estonian: Taltzi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on süstekoha valu ja punetus ning nina-, kurgu- või rindkereinfektsioon.
English: It is not intended to provide practical advice on how to use Taltz.
Estonian: Hindamisaruandes ei anta Taltzi kasutamise praktilisi nõuandeid.
English: After training, patients may inject Taltz if their doctor considers it appropriate.
Estonian: Patsiendid tohivad pärast asjakohase väljaõppe saamist süstida Taltzi endale ise, kui arst peab seda kohaseks.
English: In 2 studies, treatment was continued in patients whose psoriasis improved with Taltz given every 2 weeks for 12 weeks.
Estonian: Kahes uuringus jätkati ravi patsientidel, kelle psoriaas paranes 12 nädala jooksul iga 2 nädala järel manustatud Taltziga.
English: For the full list of all side effects and restrictions with Taltz, see the package leaflet.
Estonian: Taltzi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Taltz, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Taltzi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: By attaching to interleukin 17A, ixekizumab blocks its action and reduces the activity of the immune system and thereby reduces the symptoms of psoriasis.
Estonian: Interleukiin 17A-ga seondudes blokeerib iksekisumaab virgatsaine toime ja vähendab immuunsüsteemi aktiivsust, leevendades sellega ühtlasi psoriaasi sümptomeid.
English: Interleukin 17A is involved in immune system effects, including inflammation, that cause psoriasis.
Estonian: Interleukiin 17A osaleb immuunsüsteemi toimetes, sealhulgas psoriaasi põhjustavas põletikus.
English: How does Taltz work?
Estonian: Kuidas Taltz toimib?
English: Studies show that Taltz is effective in treating plaque psoriasis in patients who required systemic treatment.
Estonian: Uuringud tõendavad, et Taltz on efektiivne naastulise psoriaasi ravis süsteemset ravi vajavatel patsientidel.
English: The medicine has been shown to be effective in moderate to severe plaque psoriasis and its side effects are in line with other similar psoriasis medicines.
Estonian: On tõendatud, et ravim on efektiivne mõõduka kuni raske naastulise psoriaasi ravis ja selle kõrvalnähud on samalaadsed kui teistel sarnastel psoriaasiravimitel.
English: The doctor may decide to stop treatment if the condition does not improve after 16 to 20 weeks.
Estonian: Kui seisund ei ole 16-20 nädala pärast paranenud, võib arst otsustada ravi katkestada.
English: Plaque psoriasis improved to a greater extent in patients treated with Taltz than with placebo (a dummy treatment) or with etanercept, another medicine used to treat psoriasis.
Estonian: Naastuline psoriaas paranes rohkem Taltziga ravitud patsientidel kui platseebo (näiv ravim) või etanertsepti (samuti psoriaasiravim) uuringurühma patsientidel.
English: The active substance in Taltz, ixekizumab, is a monoclonal antibody, a protein designed to attach to interleukin 17A, a messenger molecule in the body's immune system (the body's natural defences).
Estonian: Taltzi toimeaine iksekisumaab on monoklonaalne antikeha (teatud valk), mis seondub organismi immuunsüsteemi (organismi loodusliku kaitsemehhanismi) virgatsainega interleukiin 17A.
English: In 3 main studies involving over 3,800 patients with psoriasis, 89% of those treated every two weeks with Taltz attained a 75% reduction in PASI scores (a measure of disease severity and area of skin affected) after 12 weeks.
Estonian: Kolmes põhiuuringus, milles osales üle 3800 psoriaasiga patsiendi, oli patsiente, kellel vähenes PASIskoor (millega mõõdetakse haiguse raskusastet ja haigusest haaratud nahapindala) pärast 12-nädalast ravi 75%, iga kahe nädala järel Taltziga ravitud patsientidest 89%.
English: Taltz can only be obtained with a prescription and it should be used under the supervision of a doctor experienced in diagnosing and treating psoriasis.
Estonian: Taltz on retseptiravim ning seda tohib kasutada psoriaasi diagnostikas ja ravis kogenud arsti järelevalve all.
English: For more information about treatment with Taltz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Taltziga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.